My Size, Inc. 10-Q

Item 1. Financial Statements. My Size, Inc. and Subsidiaries Condensed Consolidated Interim Financial Statements As of June 30, 2024 (unaudited) U.S. Dollars in Thousands 1 MY SIZE, INC. AND ITS SUBSIDIARIES Condensed Consolidated Interim Financial Statements as of June 30, 2024 (Unaudited) Contents Page Condensed Consolidated Interim Balance Sheets (Unaudited) 3 Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) 4 Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity (Unaudited) 5-6 Condensed Consolidated Interim Statements of Cash flows (Unaudited) 7 Notes to Condensed Consolidated Interim Financial Statements (Unaudited) 8-15 2 MY SIZE, INC. AND ITS SUBSIDIARIES Condensed Consolidated Interim Balance Sheets (Unaudited) U.S. dollars in thousands (except share data and per share data) June 30, December 31, 2024 2023 Assets Current Assets: Cash and cash equivalents 3,201 2,187 Restricted cash 74 77 Short term deposit - 22 Inventory 1,793 2,879 Account receivables 329 615 Other receivables and prepaid expenses 807 847 Total current assets 6,204 6,627 Long term deposits 7 7 Property and equipment, net 107 121 Operating right-of-use asset 32 351 Intangible assets 919 1,097 Goodwill 733 758 Investment in JV - 24 Investment in marketable securities 10 6 Total non-current assets 1,808 2,364 Total assets 8,012 8,991 Liabilities and stockholders’ equity Current liabilities: Operating lease liability 17 158 Bank overdraft and short-term loans 423 158 Trade payables 896 2,154 Liabilities to Related parties 70 605 Other payables 703 803 Total current liabilities 2,109 3,878 Long-term loans 193 249 Operating lease liability 15 129 Total non-current liabilities 208 378 Total liabilities 2,317 4,256 COMMITMENTS AND CONTINGENCIES - Stockholders’ equity: Stock Capital - Common stock of $ 0.001 par value - Authorized: 250,000,000 shares; Issued and outstanding: 883,131 (*) and 452,724 (*) as of June 30, 2024 and December 31, 2023, respectively 1 1 Additional paid-in capital 68,425 65,386 Accumulated other comprehensive loss ( 870 ) ( 771 ) Accumulated deficit ( 61,861 ) ( 59,881 ) Total stockholders’ equity 5,695 4,735 Total liabilities and stockholders’ equity 8,012 8,991 (*) Adjusted to give retroactive effect of 1:8 Reverse stock split, see note 8 (d) The accompanying notes are an integral part of the condensed consolidated interim financial statements. 3 MY SIZE, INC. AND ITS SUBSIDIARIES Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) U.S. dollars in thousands (except share data and per share data) 2024 2023 2024 2023 Six-Months Ended June 30, Three-Months Ended June 30, 2024 2023 2024 2023 Revenues 4,963 2,010 1,979 1,290 Cost of revenues (*) ( 2,783 ) ( 1,918 ) ( 995 ) ( 771 ) Gross profit 2,180 92 984 519 Operating expenses Research and development ( 263 ) ( 569 ) ( 131 ) ( 227 ) Sales and marketing ( 1,933 ) ( 1,646 ) ( 831 ) ( 967 ) General and administrative ( 1,932 ) ( 1,923 ) ( 899 ) ( 879 ) Total operating expenses ( 4,128 ) ( 4,138 ) ( 1,861 ) ( 2,073 ) Operating loss ( 1,948 ) ( 4,046 ) ( 877 ) ( 1,554 ) Financial income (expenses), net ( 32 ) ( 100 ) ( 87 ) 46 Equity loss of equity method investees *** - ( 39 ) - ( 5 ) Loss before taxes ( 1,980 ) ( 4,185 ) ( 964 ) ( 1,513 ) Taxes on income - 240 - 222 Net loss ( 1,980 ) ( 3,945 ) ( 964 ) ( 1,291 ) Other comprehensive income (loss): Foreign currency translation differences ( 99 ) ( 39 ) 8 ( 24 ) Total comprehensive loss ( 2,079 ) ( 3,984 ) ( 956 ) ( 1,315 ) Basic and diluted loss per share** ( 3.06 ) ( 14.40 ) ( 1.28 ) ( 4.24 ) Basic and diluted weighted average number of shares outstanding** 647,321 273,845 755,600 305,519 (*) During the six months ended June 30, 2023, the Company recorded an inventory write-down of $ 643 due to the fire that occurred in its warehouse). (**) Adjusted to give retroactive effect of 1:8 reverse stock split , see note 8 (d). (***) In March 2024, the Company closed a joint venture (the “JV”) in Brazil with Santista Têxtil. The accompanying notes are an integral part of the interim condensed consolidated financial statements. 4 MY SIZE, INC. AND ITS SUBSIDIARIES Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity (Unaudited) U.S. dollars in thousands (except share data and per share data) Number** Amount ** capital ** loss deficit equity Common stock Additional paid-in Accumulated other comprehensive Accumulated Total stockholders’ Number ** Amount ** capital ** loss deficit equity Balance as of January 1, 2024 452,724 1 65,386 ( 771 ) ( 59,881 ) 4,735 Stock-based compensation related to options granted to employees and consultants 80,000 - * 217 - - 217 Issuance of shares post Business Combination 4,360 - * 3 - - 3 Effect of reverse stock split 74,683 - * - - - - Issuance of shares, net of issuance cost of $ 442 (***) 79,000 - * 2,819 - - 2,819 Exercise of shares in abeyance 192,364 - * - - - - Total comprehensive loss - - - ( 99 ) ( 1,980 ) ( 2,079 ) Balance as of June 30, 2024 883,131 1 68,425 ( 870 ) ( 61,861 ) 5,695 (*) Represents an amount less than $1. (**) Adjusted to give retroactive effect of 1:8 reverse stock split , see note 8 (d). (***) See note 8 (f). Number** Amount ** Capital ** loss deficit equity Common stock Additional paid-in Accumulated other comprehensive Accumulated Total stockholders’ Number ** Amount ** Capital ** loss deficit equity Balance as of January 1, 2023 183,015 1 58,673 ( 637 ) ( 53,501 ) 4,536 Stock-based compensation related to options granted to employees and consultants ( 1,000 ) - * 222 - - 222 Issuance of shares, net of issuance cost of $ 341 (**) 20,250 - * 2,658 - - 2,658 Exercise of warrants and prefunded warrants 102,583 - * 1 - - 1 Total comprehensive loss - - - ( 39 ) ( 3,945 ) ( 3,984 ) Balance as of June 30, 2023 304,848 1 61,554 ( 676 ) ( 57,446 ) 3,433 (*) Represents an amount less than $1 (**) Adjusted to give retroactive effect of 1:8 reverse stock split , see note 8 (d). Number** Amount ** Capital ** loss deficit equity Common stock Additional paid-in Accumulated other comprehensive Accumulated Total stockholders’ Number ** Amount ** Capital ** loss deficit equity Balance as of April 1, 2024 641,459 1 65,527 ( 878 ) ( 60,897 ) 3,753 Stock-based compensation related to options granted to employees and consultants - 79 - - 79 Effect of reverse stock split 74,683 - * - - - - Issuance of shares, net of issuance cost of $ 442 (***) 79,000 - * 2,819 - - 2,819 Exercise of warrants and prefunded warrants 87,989 - * - - - - Total comprehensive loss - - - 8 ( 964 ) ( 956 ) Balance as of June 30, 2024 883,131 1 68,425 ( 870 ) ( 61,861 ) 5,695 (*) Represents an amount less than $1 (**) Adjusted to give retroactive effect of 1:8 reverse stock split , see note 8 (d). (***) See note 8 (f). 5 Number** Amount ** Capital ** loss deficit equity Common stock Additional paid-in Accumulated other comprehensive Accumulated Total stockholders’ Number ** Amount ** Capital ** loss deficit equity Balance as of April 1, 2023 305,848 1 61,468 ( 652 ) ( 56,155 ) 4,662 Stock-based compensation related to options granted to employees and consultants ( 1,000 ) - * 86 - - 86 Total comprehensive loss - - - ( 24 ) ( 1,291 ) ( 1,315 ) Balance as of June 30, 2023 304,848 1 61,554 ( 676 ) ( 57,446 ) 3,433 (*) Represents an amount less than $1 (**) Adjusted to give retroactive effect of 1:8 reverse stock split , see note 8 (d). Number** Amount ** capital ** loss deficit equity Common stock Additional paid-in Accumulated other comprehensive Accumulated Total stockholders’ Number ** Amount ** capital ** loss deficit equity Balance as of December 31, 2022 183,015 1 58,673 ( 637 ) ( 53,501 ) 4,536 Balance 183,015 1 58,673 ( 637 ) ( 53,501 ) 4,536 Stock-based compensation related to options and restricted shares granted to employees and consultants ( 1,000 ) - (*) 453 - - 453 Issuance of shares, net of issuance cost of $ 959 54,000 - (*) 6,258 - - 6,258 Issuance of shares, net of issuance cost 54,000 - (*) 6,258 - - 6,258 Exercise of shares in abeyance 216,709 - (*) 2 - - 2 Total comprehensive loss - - - ( 134 ) ( 6,380 ) ( 6,514 ) Balance as of December 31, 2023 452,724 1 65,386 ( 771 ) ( 59,881 ) 4,735 Balance 452,724 1 65,386 ( 771 ) ( 59,881 ) 4,735 (*) Represents an amount less than $1. (**) Adjusted to give retroactive effect of 1:8 reverse stock split , see note 8 (d). 6 MY SIZE, INC. AND ITS SUBSIDIARIES Condensed Consolidated Interim Statements of Cash Flows (Unaudited) U.S. dollars in thousands 2024 2023 Six-Months Ended June 30, 2024 2023 Cash flows from operating activities: Net loss ( 1,980 ) ( 3,945 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 16 16 Change in operating lease right-of-use asset 138 88 Amortization of intangible assets 76 151 Change in liabilities to related parties ( 525 ) ( 76 ) Interest of long-term liabilities 41 11 Interest paid ( 37 ) ( 11 ) Revaluation of investment in marketable securities ( 4 ) 23 Change in Investment in JV - 39 Stock based compensation 217 222 Change in inventory 1,080 ( 95 ) Change in deferred tax liabilities - ( 36 ) Change in account receivable 282 1,119 Changes in operating lease liabilities ( 97 ) ( 68 ) Change in other receivables and prepaid expenses 38 ( 205 ) Change in trade payables ( 1,212 ) ( 888 ) Change in other payables ( 109 ) 15 Net cash used in operating activities ( 2,076 ) ( 3,640 ) Cash flows from investing activities: Proceeds from investment in JV 38 - Proceeds from short-term deposits 22 - Net cash used in investing activities 60 - Cash flows from financing activities: Proceeds from issuance of shares, net of issuance costs 2,819 2,658 Loans received 500 - Repayment of loans ( 358 ) ( 62 ) Net cash provided by financing activities 2,961 2,596 Effect of exchange rate fluctuations on cash and cash equivalents 66 ( 69 ) Increase (decrease) in cash, cash equivalents and restricted cash (*) 1,011 ( 1,113 ) Cash, cash equivalents and restricted cash at the beginning of the period 2,264 2,363 Cash, cash equivalents and restricted cash at the end of the period 3,275 1,250 Non cash activities: Change in operating lease right-of-use asset and liability 181 - (*) $ 1,014 relates to change in cash and cash equivalents and, $( 3 ) to change in restricted cash for the six months ended June 30, 2024. The accompanying notes are an integral part of the interim condensed consolidated financial statements. 7 MY SIZE, INC. AND ITS SUBSIDIARIES Notes to Condensed Consolidated Interim Financial Statements (Unaudited) U.S. dollars in thousands (except share data and per share data) Note 1 - General a. My Size, Inc. (the “Company”) is developing unique measurement technologies based on algorithms with applications in a variety of areas, including the apparel e-commerce market, the courier services market and the Do It Yourself (“DIY”) smartphone and tablet apps market. The technology is driven by proprietary algorithms, which are able to calculate and record measurements in a variety of novel ways. Following the acquisition of Naiz Fit Bespoke Technologies, S.L (“Naiz”) in October 2022, the Company expanded its offering outreach and customer base. Following the acquisition of Orgad International Marketing Ltd. (“Orgad”) in February 2022, the Company also operates an omnichannel e-commerce platform. The Company has six subsidiaries, My Size Israel 2014 Ltd. (“My Size Israel”), Topspin Medical (Israel) Ltd., Orgad and Rotrade Ltd., all of which are incorporated in Israel, My Size LLC, which is incorporated in the Russian Federation and Naiz, a limited liability company incorporated under the laws of Spain. References to the Company include the subsidiaries unless the context indicates otherwise. My Size, Inc., was incorporated and commenced operations in September 1999, as Topspin Medical Inc. (“Topspin”), a private company registered in the State of Delaware. In December 2013, the Company changed its name to Knowledgetree Ventures Inc. Subsequently, in February 2014, the Company changed its name to My Size, Inc. Topspin was engaged, through its Israeli subsidiary, in research and development in the field of cardiology and urology. On July 25, 2016, the Company’s common stock began publicly trading on the Nasdaq Capital Market under the symbol “MYSZ”. From September 1, 2005 to March 27, 2024, the Company’s common stock was traded on the Tel Aviv Stock Exchange. b. Since inception, the Company has incurred significant losses and negative cash flows from operations and had an accumulated deficit of $ 61,861 . The Company has financed its operations mainly through fundraising from various investors. The Company’s management expects that the Company will continue to generate losses and negative cash flows from operations for the foreseeable future. Based on the projected cash flows and cash balances as of June 30, 2024, management is of the opinion that its existing cash will not be sufficient to fund operations for a period of more than 12 months. As a result, there is substantial doubt about the Company’s ability to continue as a going concern. Management’s plans include the continued commercialization of the Company’s products and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to cease operations. The financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern. c. In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries, and Hamas additionally kidnapped many Israeli civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas and other terrorist organizations in parallel to their continued rocket and terror attacks. In addition, since the commencement of these events, there have been continued hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen). It is possible that hostilities with Hezbollah in Lebanon will escalate, and that other terrorist organizations, including Palestinian military organizations in the West Bank as well as other hostile countries will join the hostilities. In addition, Iran recently launched a direct attack on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. Such clashes may escalate in the future into a greater regional conflict. The war with Hamas has had an immaterial effect on its operations and financial results so far. This is attributable to its global footprint and the offices in Spain, which has become a hub for the Company’s sizing solutions business. The majority of Orgad’s inventory utilizes fulfillment by Amazon rather than fulfilling directly. Inventory is now maintained and orders are shipped from regional Amazon warehouses, thereby reducing exposure to inventory risk and contributing to operating efficiencies. On February 24, 2022, Russia invaded Ukraine. The outbreak of hostilities between the two countries could result in more widespread conflict and could have a severe adverse effect on the region. Following Russia’s actions, various countries, issued broad-ranging economic sanctions against Russia. Such sanctions included, among other things, a prohibition on doing business with certain Russian companies, officials and oligarchs; a commitment by certain countries and the European Union to remove selected Russian banks from the Society for Worldwide Interbank Financial Telecommunications (SWIFT) electronic banking network that connects banks globally; and restrictive measures to prevent the Russian Central Bank from undermining the impact of the sanctions. The Company shut down its operation in Russia and expected to close down its subsidiary, My Size LLC, but due to technical reasons it is expected to occur in the near future; therefore, the impact from the current situation is very limited. 8 MY SIZE, INC. AND ITS SUBSIDIARIES Notes to Condensed Consolidated Interim Financial Statements (Unaudited) U.S. dollars in thousands (except share data and per share data) Note 2 - Significant Accounting Policies a. Unaudited condensed consolidated financial statements: The accompanying unaudited condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The unaudited condensed consolidated financial statements are comprised of the financial statements of the Company. In management’s opinion, the interim financial data presented includes all adjustments necessary for a fair presentation. All intercompany accounts and transactions have been eliminated. Operating results for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2023. b. Significant Accounting Policies: The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements. c. Critical accounting estimates: ASC 350 requires goodwill to be tested for impairment at the reporting unit level at least annually, or between annual tests under certain circumstances, and written down when impaired. Goodwill is tested for impairment by comparing the fair value of the reporting unit with it carrying value. During the first and second quarters of 2024, there was no more likely than not indication of impairment; therefore, no further impairment testing was required. d. Recent adopted accounting pronouncements: In June 2022, the FASB issued ASC 2022-03 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The ASU clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring its fair value. The ASU also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The ASU also introduces new disclosure requirements for equity securities subject to contractual sale restrictions. The ASU do not have a material impact on the Company consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related earnings per share guidance. This standard became effective for the Company beginning on January 1, 2024. Adoption is either a modified retrospective method or a fully retrospective method of transition. The Company adopted this guidance effective January 1, 2024, and the adoption of this standard did not have a material impact on its consolidated financial statements. Note 3 – Financial Instruments The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, other receivables, trade payables and accounts payable approximate their fair value due to the short-term maturities of such instruments. The Company holds share certificates in iMine Corporation (“iMine”), formerly known as Diamante Minerals, Inc., a publicly traded company on the OTCQB. Due to sales restrictions on the sale of the iMine shares, the fair value of the shares was measured on the basis of the quoted market price for an otherwise identical unrestricted equity instrument of the same issuer that trades in a public market, adjusted to reflect the effect of the sales restrictions and is therefore, ranked as Level 2 assets. Schedule of Significant Assets and Liabilities Measured at Fair Value on Recurring Basis June 30, 2024 Fair value hierarchy Level 1 Level 2 Level 3 Financial assets Investment in marketable securities (*) - 10 - 9 MY SIZE, INC. AND ITS SUBSIDIARIES Notes to Condensed Consolidated Interim Financial Statements (Unaudited) U.S. dollars in thousands (except share data and per share data) Note 3 - Financial Instruments (Cont.) December 31, 2023 Fair value hierarchy Level 1 Level 2 Level 3 Financial assets Investment in marketable securities (*) - 6 - (*) For the six and three-month periods ended June 30, 2024 and 2023, the Company recognized gain (loss) (based on quoted market prices with a discount due to security restrictions on iMine shares) of the marketable securities was $ 4 , $( 21 ), $( 1 ) $and $( 7 ), respectively. Note 4 - Stock Based Compensation The stock-based expense equity awards recognized in the financial statements for services received is related to Cost of Revenues, Research and Development, Sales and Marketing and General and Administrative expenses as shown in the following table: Schedule of Stock Based Compensation Expenses 2024 2023 2024 2023 Six months ended June 30, Three months ended June 30, 2024 2023 2024 2023 Stock-based compensation expense – Cost of revenues 1 15 - 6 Stock-based compensation expense - Research and development 29 29 16 6 Stock-based compensation expense - Sales and marketing 24 55 8 15 Stock-based compensation expense - General and administrative 166 123 55 59 Stock-based compensation expense 220 222 79 86 10 MY SIZE, INC. AND ITS SUBSIDIARIES Notes to Condensed Consolidated Interim Financial Statements (Unaudited) U.S. dollars in thousands (except share data and per share data) Note 4 - Stock Based Compensation (Cont.) Stock Option Plan for Employees: In March 2017, the Company adopted the My Size, Inc. 2017 Equity Incentive Plan (the “2017 Employee Plan”) pursuant to which the Company’s Board of Directors may grant stock options and other equity awards to officers and key employees. The total number of shares of common stock which may be granted to directors, officers, employees under this plan, is limited to 130,000 shares. Stock options can be granted with an exercise price equal to or less than the stock’s fair market value at the date of grant. On December 27, 2023, the Company’s stockholders approved an increase in the shares available for issuance under the 2017 Equity Incentive Plan from 36,125 shares to 130,000 shares. On February 14, 2024, the Compensation Committee of the Company granted restricted common stock awards under the Company’s 2017 Equity Incentive Plan to Ronen Luzon, Or Kles and Billy Pardo, pursuant to which they were issued 37,500 restricted shares, 18,750 restricted shares and 18,750 restricted shares, respectively. The restricted shares shall vest in three equal installments on January 1, 2025, January 1, 2026 and January 1, 2027, conditioned upon continuous employment with the Company and subject to accelerated vesting upon a change in control of the Company. On the same day, the Company granted a total of 10,000 restricted stock units (“RSUs”) to its directors that will vest on January 1, 2025 and five-years options to purchase up to 6,875 shares of common stock to other employees of the Company at an exercise price of $ 3.832 per share. The option vesting period is over three years in three equal portions from the vesting commencement date. The fair value of each option award is estimated on the date of grant using the Binomial option-pricing model that used the weighted average assumptions in the following table. The risk free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant Schedule of Fair Value Assumptions of Stock Option 2024 Grants Dividend yield 0 % Expected volatility 86.22 % Risk-free interest 4.3 % Contractual term 2.0 - 2.8 During the six and three-month periods ended June 30, 2024, the Company granted options, restricted stock and RSUs to purchase 91,875 and 0 shares of common stock under the 2017 Employee Plan (as described above), respectively. No options were exercised and 4,000 options expired. The total stock option compensation expense for employees during the six and three-month periods ended June 30, 2024 and 2023 was $ 146 , $ 79 , $ 162 and $ 44 , respectively. The total stock option compensation expense relating to the Orgad acquisition during the six and three-month periods ended June 30, 2024 and 2023 was $ 3 , $ 0 , $ 60 and $ 118 , respectively. Options issued to consultants: In July 2023, the Company entered into a six month agreement (the “Consultant Agreement”) with a consultant (the “Consultant”) to provide services to the Company, including assisting the Company to promote, market and sell the Company’s technology to potential customers and make strategic introductions and inquiries with interested parties in the financial community. Pursuant to the Consultant Agreement and in partial consideration for such consulting services, the Company issued to the Consultant (i) 5,000 shares of restricted common stock of the Company, (ii) a warrant to purchase 12,500 shares of common stock at an exercise price of $4.00 per share and exercisable for a term of 36 months from the date of issuance, and (iii) a warrant to purchase 12,500 shares of common stock at an exercise price of $6.00 per share and exercisable for a term of 36 months from the date of issuance . The issuance was approved by the Company’s board of directors in February 2024. During the six and three-month periods ended June 30, 2024, the Company recorded $ 71 and $ 0 , respectively, as stock-based equity awards with respect to the Consultant. No expenses were recorded in the fiscal year ended December 31, 2023 with respect to the Consultant. 11 MY SIZE, INC. AND ITS SUBSIDIARIES Notes to Condensed Consolidated Interim Financial Statements (Unaudited) U.S. dollars in thousands (except share data and per share data) Note 5 - Contingencies and Commitments a. On August 7, 2018, the Company commenced an action against North Empire LLC (“North Empire”) in the Supreme Court of the State of New York, County of New York for breach of a Securities Purchase Agreement (the “Agreement”) in which it is seeking damages in an amount to be determined at trial, but in no event less than $ 616 . On August 2, 2018, North Empire filed a Summons with Notice against the Company, also in the same Court, in which they allege damages in an amount of $ 11,400 arising from an alleged breach of the Agreement. On September 6, 2018 North Empire filed a Notice of Discontinuance of the action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action commenced by the Company against them, alleging that the Company failed to deliver stock certificates to North Empire causing damage to North Empire in the amount of $ 10,958 . North Empire also filed a third-party complaint against the Company’s CEO and now former Chairman of the Board asserting similar claims against them in their individual capacities. On October 17, 2018, the Company filed a reply to North Empire’s counterclaims. On November 15, 2018, the Company’s CEO and now former Chairman of the Board filed a motion to dismiss North Empire’s third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint. Discovery has been completed and both parties have filed motions for summary judgment in connection with the claims and counterclaims. On December 30, 2021, the Court denied both the Company and North Empire’s motions for summary judgment, arguing there were factual issues to be determined at trial. On January 26, 2022, the Company filed a notice of appeal of the summary judgment decision. On February 3, 2022, the Company filed a motion to reargue the Court’s decision denying the Company’s motion for summary judgment. North Empire will file its opposition papers on or before March 31, 2022, and the Company will file reply papers on April 29, 2022. On or about September 12, 2022, the Court issued its Decision and Order denying the Company’s motion to reargue. North Empire filed its opposing brief on December 7, 2022. Both sides were given an opportunity to file a reply brief. The Company filed a reply brief on January 4, 2023 and North Empire filed its reply brief on January 13, 2023. The Appellate Court has scheduled oral argument for the appeal for February 7, 2023. Oral argument was held before the Appellate Court on February 7, 2023. On or about February 28, 2023, the Appellate Court filed its Decision and Order, which affirmed the lower court’s decisions regarding both the Company and North Empire’s motions for summary judgment and sent the case back to the Supreme Court. On March 13, 2023, the Supreme Court referred the case to its Alternative Dispute Program and ordered the cases to mediate. The mediation was held on July 26, 2023 and various settlement options were explored but the mediation did not lead to settlement. On December 21, 2023, a conference with the Court was held and the parties were given dates for various pre-trial filings. The parties are exploring a resolution and the Court has adjourned the pre-trial deadlines. On July 30, 2024, the parties provided the Court with a status update regarding a possible resolution of the action. As such, the Court has instructed the parties to provide a further update on August 13, 2024. The Company intends to vigorously defend any claims made by North Empire. The Company believes it is more likely than not that the counterclaims will be denied. b. In July 2024, the Company was served with a legal complaint filed by Shimon Shukron in the Magistrate’s Court in Herzliya for a monetary award in an amount of NIS 1,895,345 (approximately $ 510 ). The plaintiff alleges that due to the fire that broke out at Orgad’s warehouse in January 2023, the fire spread to the plaintiff’s business and caused heavy damage to the structure and contents, inventory of the business and loss of profits. The Company plans to file its statement of defense in September 2024. At this preliminary stage, before any fact finding and pre-trial procedures (including disclosure of documents) have been conducted and before the statement of defense has been prepared and filed, the Company cannot evaluate the chances of the claim to succeed. Note 6 - Goodwill During the third quarter of 2023, the Company merged its two software-as-a-service (“SaaS”) segments into one segment (see Note 7), which also resulted in a change in the Company’s composition of reporting units. In the Company’s financial reporting for June 30, 2024, comparative information for 2023 was restated to reflect the changes in reportable segments. After the restructuring, the aggregate carrying amounts of goodwill allocated to each reporting unit are as follows: Schedule of Aggregate Carrying Amount Of Goodwill 2024 2023 June 30 2024 2023 SaaS Solutions 603 1,271 Fashion and equipment e-commerce platform 130 132 Total 733 1,403 12 MY SIZE, INC. AND ITS SUBSIDIARIES Notes to Condensed Consolidated Interim Financial Statements (Unaudited) U.S. dollars in thousands (except share data and per share data) Note 7 – Operating Segments Effective July 1, 2023 the Company merged its two SaaS segments into one segment, reducing its reportable segments from three to the following two segments: (i) fashion and equipment e-commerce platform, and (ii) SaaS based innovative artificial intelligence driven measurement solutions. This realignment reflects the way resources are allocated and performance is assessed by the Chief Operating Decision Maker. The fashion and equipment e-commerce platform which represents Orgad’s activity that was acquired by the Company in 2022, mainly operates on Amazon. The SaaS based innovative artificial intelligence driven measurement solutions, or SaaS Solutions operating segment consists of My Size Inc., My Size Israel, My Size LLC and Naiz Fit. In the Company’s financial reporting for six and three-month periods ended June 30, 2024, comparative information for 2023 was restated to reflect the changes in reportable segments. Information related to the operations of the Company’s reportable operating segments is set forth below: Schedule of Reportable Operating Segments Fashion and equipment e-commerce platform SaaS Solutions Total As of the six months ended June 30, 2024 Revenues from external customers 4,623 340 4,963 Operating loss ( 1,042 ) ( 906 ) ( 1,948 ) Fashion and equipment e-commerce platform Saas Solution As of June 30, 2024: 5,672 2,340 Assets Fashion and equipment e-commerce platform SaaS Solutions Total As of the six months ended June 30, 2023 Revenues from external customers 1,738 272 2,010 Operating loss ( 2,495 ) ( 1,551 ) ( 4,046 ) 13 MY SIZE, INC. AND ITS SUBSIDIARIES Notes to Condensed Consolidated Interim Financial Statements (Unaudited) U.S. dollars in thousands (except share data and per share data) Note 7 – Operating Segments (Cont.) Fashion and equipment e-commerce platform SaaS Solutions Total As of the three months ended June 30, 2024 Revenues from external customers 1,816 163 1,979 Operating loss ( 460 ) ( 417 ) ( 877 ) Fashion and equipment e-commerce platform SaaS Solutions Total As of the three months ended June 30, 2023 Revenues from external customers 1,160 130 1,290 Operating loss ( 818 ) ( 736 ) ( 1,554 ) Fashion and equipment e-commerce platform SaaS Solutions Total As of the year ended December 31, 2023 Revenues from external customers 6,367 629 6,996 Operating loss ( 3,356 ) ( 3,385 ) ( 6,741 ) Fashion and equipment e-commerce platform SaaS Solutions As of December 31, 2023: Assets 6,352 2,639 14 MY SIZE, INC. AND ITS SUBSIDIARIES Notes to Condensed Consolidated Interim Financial Statements (Unaudited) U.S. dollars in thousands (except share data and per share data) Note 8 – Significant events during the reporting period a. Further to note 16 to the Company’s 10-K for the year ended December 31, 2023, which was filed with the SEC on April 1, 2024, the Company agreed to pay to the former owners of Orgad on the two-year and the three-year anniversary anniversaries of the closing of the transaction pursuant to which the Company acquired 100 % of the shares and voting interests in Orgad, $ 350 in each of these years, provided that in the case of the second and third instalments certain revenue targets are met and subject further to certain downward post-closing adjustment. In February 2024, the amount of $ 700 was fully paid to the former owners of Orgad net of a settlement amount of $ 275 . b. On January 8, 2024, the Company provided a notice of six month termination to the lessor that the office lease agreement will end on July 8, 2024 instead of August 20, 2025. As a result the Company reduced its “Right of use asset” against current liabilities as “Operating lease liability” and in the non-current liabilities as “Operating lease liability – long term” on the Company’s June 30, 2024 consolidated balance sheets in an amount of $ 181 . c. During February 2024, the Company received a loan from a commercial lender in an amount of $ 500 . The loan bears interest at a fix rate of 6 % of the principal and payable in installments during six month term. d. On April 19, 2024, the Company effected a one-for-eight reverse stock split of its common stock (the “Reverse Stock Split”) with the Company’s shares beginning trading on a post-split basis on the Nasdaq Capital Market on April 23, 2024. Upon the Reverse Stock Split, every eight shares of the Company’s issued and outstanding common stock was automatically converted into one share of common stock, without any change in the par value per share. In addition, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options and warrants entitling the holders to purchase common stock. Any fraction of a share of common stock that would otherwise have resulted from the Reverse Stock Split was rounded up to the next whole number. e. On November 3, 2023, the Company was notified, by the Nasdaq Listing Qualifications that the Company is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq. The Notification Letter provided that the Company had 180 calendar days, or until May 1, 2024, to regain compliance with the Rule. To regain compliance, the bid price of the Company’s common stock must have had a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. On May 7, 2024, the Company received a letter from Nasdaq that, for the 10 consecutive business days from April 23, 2024 to May 6, 2024, the closing bid price of the Company’s common stock had been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed . f. On May 16, 2024, the Company entered into an inducement offer letter agreement (the “Inducement Letter”) with a certain holder (the “Holder”) of certain of the Company’s existing warrants to purchase up to (i) 326,514 shares of the Company’s common stock issued on August 28, 2023 with a twenty-eight month term at an exercise price of $ 16.72 per share and (ii) 344,475 shares of the Company’s common stock issued on August 28, 2023 with a five and one-half year term at an exercise price of $ 16.72 per share, ((i) and (ii) collectively, the “Existing Warrants). Pursuant to the Inducement Letter, the Holder agreed to exercise for cash its Existing Warrants to purchase an aggregate of 670,989 shares of the Company’s common stock at a reduced exercise price of $ 4.86 per share in consideration of the Company’s agreement to issue new common stock purchase warrants (the “New Warrants”) to purchase up to an aggregate of 1,341,978 shares of the Company’s common stock, at an exercise price of $ 4.61 per share. The Company received aggregate gross proceeds of approximately $ 3.26 million from the exercise of the Existing Warrants by the Holder, before deducting placement agent fees and other offering expenses payable by the Company. As of June 30, 2024, the Company issued to the Holder 166,989 of the shares exercised with the remaining 504,000 share held in abeyance. The Company engaged H.C. Wainwright & Co., LLC (the “Placement Agent”) to act as its exclusive placement agent in connection with the transactions contemplated by the Inducement Letter and paid the Placement Agent a cash fee equal to 7.0 % of the aggregate gross proceeds received from the Holder’s exercise of the Existing Warrants, as well as a management fee equal to 1.0 % of the gross proceeds from the exercise of the Existing Warrants. Upon exercise for cash of any New Warrants, the Company has agreed in certain circumstances to pay the Placement Agent a cash fee of 7.0 % of the aggregate gross exercise price paid in cash with respect the exercise of the New Warrants, and a management fee of 1.0 % of the aggregate gross exercise price paid in cash with respect to the New Warrants. The Company also issued to the Placement Agent or its designees warrants (the “Placement Agent Warrants”) to purchase up to 46,969 shares of common stock (representing 7.0 % of the Existing Warrants being exercised), which have the same terms as the New Warrants except the Placement Agent Warrants have an exercise price equal to $ 6.075 per share ( 125 % of the reduced exercise price of the Existing Warrants). Similar to the New Warrants, the Placement Agent Warrants were immediately exercisable from the date of issuance until the five and one-half year anniversary of such date. In addition, the Company paid the Placement Agent up to $ 85 for non-accountable expenses and other out-of-pocket expenses and $ 16 for clearing fees. 15